Tue, 29 Jul 2025

Tue, 29 Jul 2025 Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.

  >>


Terms of Use | Privacy Policy | Manage Cookies+ | Ad Choices | Accessibility & CC | About | Newsletters | Transcripts
Business News Top © 2024-2025